SLC39A7 and breast carcinoma: Moreover, the models of Faslodex® resistant breast cancer did not show the same increased activation of downstream pathways which have been directly linked to ZIP7 activation, such as AKT (and to a lesser degree MAPK),17 in the TamR cells.